Argent BioPharma Limited
RGTLF
$0.0599
$0.011423.51%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -98.54% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -98.54% | |||
| Cost of Revenue | -7.69% | -99.41% | |||
| Gross Profit | 0.00% | 100.16% | |||
| SG&A Expenses | -2.75% | -13.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -2.77% | 128.62% | |||
| Total Operating Expenses | -2.75% | -13.24% | |||
| Operating Income | 2.75% | 10.75% | |||
| Income Before Tax | 2.75% | -18.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.75% | -18.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.75% | -18.29% | |||
| EBIT | 2.75% | 10.75% | |||
| EBITDA | 2.75% | 11.03% | |||
| EPS Basic | 2.74% | -18.93% | |||
| Normalized Basic EPS | 2.57% | -4.57% | |||
| EPS Diluted | 2.74% | -18.93% | |||
| Normalized Diluted EPS | 2.57% | -4.57% | |||
| Average Basic Shares Outstanding | 0.00% | -0.50% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||